Zev S. Scherl

AppTec Laboratory Services, Inc. provides testing services to the biopharmaceutical and medical device industries. The company's services include testing, contract R&D, cGMP manufacturing, tissue-based, combination products, and cellular therapeutics. The company was founded by Bonita L. Baskin in 1989 and is headquartered in St. Paul, MN.

Core Essence Orthopaedics, Inc. develops and manufactures minimally invasive soft tissue and arthroscopic musculoskeletal surgical solutions. It offers knotless suture fixation systems, compression devices, suture anchor systems, and synchronized endoscopic guide systems for feet/ankles. The company was founded by Alan B. Miller, Shawn T. Huxel and Jeffrey B. Miller in 2007 and is headquartered in Fort Yardley, PA.

NB Therapeutics, Inc. develops pharmacologic therapies. The firm has two technology platforms: iontophoresis and nitric oxide gas, through these two technology platforms it seeks to address the inherent challenges of drug delivery for diseases of the skin and nails. The company was founded by Frank J. McCaney in 2006 and is headquartered in Bristol, PA.

AV Solutions LLC retails audio visual equipment. It offers broadcasts and webcasts, studios and on productions, video productions, and national wide audiovisual services. The company was founded by Doug Mack in 2005 and is headquartered in Fairfield, NJ.

MXY D, Inc. is a pooled investment fund, which engages in the production of cannabis products. The company is headquartered in Long Beach, CA.

Mxy C, Inc. produces and distributes cannabis products. The company is headquartered in Long Beach, CA.

Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist.

EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products.

Vecta Ltd. develops products for the gastrointestinal diseases. Its product VECAM-111 meets a well-known unmet need to address symptoms of gastroesophageal reflux disease (GERD) that are not commonly addressed by existing therapeutic options. The company develops enhanced novel drug formulation for symptomatic GERD. Vecta was founded by Yehuda Chowers and Dan J. Gelvan in 2001 and is headquartered in Ramat Gan, Israel.